Latest Information

New Immunoassay May Help Detect Kidney Cancer.

March 14, 2013.

A new immunoassay shows promise as a screening tool for detecting early renal cell carcinoma (RCC).

Kidney Tumor Ablation Ideal for Selected Patients

February 06, 2013

Ablation therapies are a particularly good option for patients who are not fit for surgery. The ideal tumor is small (less than 5 cm), peripheral, and exophytic. Ablation also is safer than surgery. The complication rate for laparoscopic partial nephrectomy is 30%, compared with less than 10% for cryotherapy and 2%-7% with RFA.

Kidney Cancer Biomarkers Remain Elusive

February 06, 2013

Although clinicians have drugs that are effective in treating metastatic renal cell carcinoma (RCC), they still have no biomarkers to predict therapeutic response. Rosalie Fisher, MD, Clinical Research Fellow at the Royal Marsden Hospital in London, told attendees at the Renal and Bladder Cancer 4th National Conference.

Tandutinib Not Effective For mRCC

Source: RADAR

April 26, 2012

A small phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases (FLT3), has concluded that the novel agent has no clinical activity and excessive toxicity, and should not be developed further for mRCC (Shepard et al. Invest New Drugs 2012;30:364-367; www.ncbi.nlm.nih.gov/pubmed/20711630).

Ten patients with mRCC refractory to first-line therapies received tandutinib 500 mg BID. No patient received more than two cycles of therapy. All patients were withdrawn from the study due to disease progression (70%) or toxicity (30%); 60% of subjects required a dose reduction due to adverse events. The most common grade 3 toxicity was fatigue, which occurred in 30%.

The drug has shown anti-leukemic activity in acute myelogenous leukemia in a phase I trial, although generalized muscular weakness and fatigue were dose-limiting toxicities (DeAngelo et al. Blood 2006;108:3674-3681; www.ncbi.nlm.nih.gov/pubmed?term=DeAngelo%202006%203674).

Filed Under: Uncategorized